Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer immunotherapy products. We utilize the bodyâs own machinery â the T-cell â to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets on cancer cells. We engineer a patientâs own T-cells to express our SPEAR TCRs to target and potentially destroy tumors. Source
No articles found.
Nephros is a commercial stage company that develops and sells high performance wat...
Nephros is a commercial stage company that deve...
STRATA Skin Sciences is a medical technology company focused on the therapeutic an...
STRATA Skin Sciences is a medical technology co...
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on a...
Concert Pharmaceuticals is a clinical stage bio...
KindredBio is focused on bringing breakthrough human products and innovative new t...
KindredBio is focused on bringing breakthrough ...
La Jolla Pharmaceutical Company is a publicly traded biopharmaceutical company foc...
La Jolla Pharmaceutical Company is a publicly t...
Genocea is a biopharmaceutical company developing personalized cancer immunotherap...
Genocea is a biopharmaceutical company developi...
At Delee were fundamentally changing not only the way cancer is detected but also...
At Delee were fundamentally changing not only ...
Join the National Investor Network and get the latest information with your interests in mind.